KMO and Parkinson disease: Given the emerging prominence of aberrant mitochondrial quality control in the pathology of several disorders including Huntington’s [57,58], Alzheimer’s [59] and Parkinson’s diseases [60–63], we felt it was important to investigate potential mitochondrial functions of KMO, which is localised to the OMM [64].